Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
5
pubmed:dateCreated
2008-4-15
pubmed:abstractText
In 2 consecutive prospective clinical trials, we evaluated the efficacy of sirolimus together with a calcineurin inhibitor (cyclosporine or tacrolimus) and low-dose methotrexate for prevention of graft-versus-host disease (GVHD) after unrelated hematopoietic cell transplantation (HCT). Nine patients received sirolimus with cyclosporine, and 17 received sirolimus with tacrolimus. The incidence of grade II-IV GVHD was 77%, with the median onset at day 7 after HCT. Because of toxicity, administration of sirolimus was discontinued earlier than planned in 11 patients, but after the onset of GVHD. Three patients developed renal failure requiring hemodialysis. Accrual in both studies was terminated because of lack of efficacy. In these studies, the addition of sirolimus to regimens containing a calcineurin inhibitor and methotrexate appeared to cause toxicity and provided no detectable improvement in preventing GVHD.
pubmed:grant
pubmed:commentsCorrections
http://linkedlifedata.com/resource/pubmed/commentcorrection/18410895-10221490, http://linkedlifedata.com/resource/pubmed/commentcorrection/18410895-10516680, http://linkedlifedata.com/resource/pubmed/commentcorrection/18410895-10963197, http://linkedlifedata.com/resource/pubmed/commentcorrection/18410895-10979948, http://linkedlifedata.com/resource/pubmed/commentcorrection/18410895-11172139, http://linkedlifedata.com/resource/pubmed/commentcorrection/18410895-11773890, http://linkedlifedata.com/resource/pubmed/commentcorrection/18410895-12730113, http://linkedlifedata.com/resource/pubmed/commentcorrection/18410895-12742462, http://linkedlifedata.com/resource/pubmed/commentcorrection/18410895-12742465, http://linkedlifedata.com/resource/pubmed/commentcorrection/18410895-12742496, http://linkedlifedata.com/resource/pubmed/commentcorrection/18410895-15111931, http://linkedlifedata.com/resource/pubmed/commentcorrection/18410895-15111932, http://linkedlifedata.com/resource/pubmed/commentcorrection/18410895-15273705, http://linkedlifedata.com/resource/pubmed/commentcorrection/18410895-15625544, http://linkedlifedata.com/resource/pubmed/commentcorrection/18410895-16042691, http://linkedlifedata.com/resource/pubmed/commentcorrection/18410895-16338616, http://linkedlifedata.com/resource/pubmed/commentcorrection/18410895-1688572, http://linkedlifedata.com/resource/pubmed/commentcorrection/18410895-17138818, http://linkedlifedata.com/resource/pubmed/commentcorrection/18410895-17138825, http://linkedlifedata.com/resource/pubmed/commentcorrection/18410895-1715165, http://linkedlifedata.com/resource/pubmed/commentcorrection/18410895-18640579, http://linkedlifedata.com/resource/pubmed/commentcorrection/18410895-3513012, http://linkedlifedata.com/resource/pubmed/commentcorrection/18410895-7581076, http://linkedlifedata.com/resource/pubmed/commentcorrection/18410895-8429851, http://linkedlifedata.com/resource/pubmed/commentcorrection/18410895-9521984, http://linkedlifedata.com/resource/pubmed/commentcorrection/18410895-9746768
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
May
pubmed:issn
1523-6536
pubmed:author
pubmed:issnType
Electronic
pubmed:volume
14
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
531-7
pubmed:dateRevised
2010-8-27
pubmed:meshHeading
pubmed:year
2008
pubmed:articleTitle
Sirolimus in combination with cyclosporine or tacrolimus plus methotrexate for prevention of graft-versus-host disease following hematopoietic cell transplantation from unrelated donors.
pubmed:affiliation
Division of Clinical Research, Fred Hutchinson Cancer Research Center, University of Washington School of Medicine, Seattle, WA 98109-1024, USA. tfurlong@fhcrc.org
pubmed:publicationType
Journal Article, Research Support, N.I.H., Extramural